Grela-Wojewoda A, Pacholczak-Madej R, Adamczyk A, Korman M, Püsküllüoğlu M. Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer. Int J Mol Sci. 2022;23(5):2815. https://doi.org/10.3390/ijms23052815.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763.

Article  PubMed  Google Scholar 

Lamore SD, Kohnken RA, Peters MF, Kolaja KL. Cardiovascular Toxicity Induced by Kinase Inhibitors: Mechanisms and Preclinical Approaches. Chem Res Toxicol. 2020;33(1):125–36. https://doi.org/10.1021/acs.chemrestox.9b00387.

Article  CAS  PubMed  Google Scholar 

Lee PY, Yeoh Y, Low TY. A recent update on small-molecule kinase inhibitors for targeted cancer therapy and their therapeutic insights from mass spectrometry-based proteomic analysis. FEBS J. 2022. https://doi.org/10.1111/febs.16442.

Article  PubMed  PubMed Central  Google Scholar 

Jin Y, Xu Z, Yan H, He Q, Yang X, Luo P. A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors. Front Pharmacol. 2020;12(11):891. https://doi.org/10.3389/fphar.2020.00891.

Article  CAS  Google Scholar 

Mascolo A, Scavone C, Ferrajolo C, Rafaniello C, Danesi R, Del Re M, et al. Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance. Drug Saf. 2021;44(9):957–71. https://doi.org/10.1007/s40264-021-01086-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ning L, Hu C, Lu P, et al. Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study. Exp Hematol Oncol. 2020;9:29. https://doi.org/10.1186/s40164-020-00185-z.

Article  PubMed  PubMed Central  Google Scholar 

Ma GL, Murphy JD, Martinez ME, Sicklick JK. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev. 2015;24(1):298–302. https://doi.org/10.1158/1055-9965.epi-14-1002.

Article  PubMed  Google Scholar 

Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020;11(3):79–87. https://doi.org/10.14740/wjon1279.

Article  PubMed  PubMed Central  Google Scholar 

Santoro M, Mancuso S, Accurso V, Di Lisi D, Novo G, Siragusa S. Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review. Front Physiol. 2021;12:675811. https://doi.org/10.3389/fphys.2021.675811.

Article  PubMed  PubMed Central  Google Scholar 

Noth I, Wijsenbeek M, Kolb M, Bonella F, Moros L, Wachtlin D, et al. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials. Eur Respir J. 2019;54(3):1801797. https://doi.org/10.1183/13993003.01797-2018.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruggiero R, Fraenza F, Scavone C, di Mauro G, Piscitelli R, Mascolo A, et al. Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database. Front Pharmacol. 2020;9(11):830. https://doi.org/10.3389/fphar.2020.00830.

Article  CAS  Google Scholar 

Noseda R, Bonaldo G, Motola D, Stathis A, Ceschi A. Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase. Cancers (Basel). 2021;13(5):1131. https://doi.org/10.3390/cancers13051131.

Article  PubMed  Google Scholar 

Raschi E, Mazzarella A, Antonazzo IC, Bendinelli N, Forcesi E, Tuccori M, et al. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. Target Oncol. 2019;14(2):205–21. https://doi.org/10.1007/s11523-019-00632-w.

Article  PubMed  Google Scholar 

Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022;23(10):e333–465.

Article  PubMed  Google Scholar 

Cirmi S, El Abd A, Letinier L, Navarra M, Salvo F. Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS). Cancers (Basel). 2020;12(4):826. https://doi.org/10.3390/cancers12040826.

Article  CAS  PubMed  Google Scholar 

Hou W, Ding M, Li X, Zhou X, Zhu Q, Varela-Ramirez A, et al. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials. J Cancer Res Clin Oncol. 2021;147(8):2407–20. https://doi.org/10.1007/s00432-021-03521-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889–97. https://doi.org/10.1093/eurheartj/ehz766.

Article  PubMed  PubMed Central  Google Scholar 

Vallerio P, Orenti A, Tosi F, Maistrello M, Palazzini M, Cingarlini S, et al. Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management. ESMO Open. 2022;7(1):100338. https://doi.org/10.1016/j.esmoop.2021.100338.

Article  CAS  PubMed  Google Scholar 

Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag. 2017;4(13):293–303. https://doi.org/10.2147/vhrm.s108874.

Article  CAS  Google Scholar